Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

16260 Ventura Blvd., Suite 140
Encino, CA 91436
Phone: 818-528-7776

January 23, 2018 by Alan Khadavi

Nucala (mepolizumab) vs. Cinqair (reslizumab)

In a study published in The American Journal of Respiratory Critical Care Medicine, investigators compared intravenous reslizumab (Cinqair) and mepolizumab (Nucala).  Both of them are used for moderate to severe persistent asthma and they both neutralize IL-5, which produces blood eosinophilia and leads to severe eosinophilic asthma.

A randomized, placebo controlled trial was used to assess the efficacy of intravenous Cinqair in 10 patients with eosinophilic asthma whom a 1 year trial of subcutaneous Nucala (100 mg every 4 weeks) failed.  All patients received 2 IV infusions of placebo followed by 4 infusions of Cinqair (3 mg/kg) or placebo.

Compared with placebo, Cinqair decreased sputum eosinophil counts, blood eosinophil counts and sputum eosinophil peroxidase levels.  Patients on Cinqair had greater improvements in Asthma Control Questionnaire scores.  The investigators summarized that intravenous reslizumab (Cinqair) is superior to subcutaneous mepolizumab (Nucala) in controlling severe asthma.

This was a very, very small study with only 10 patients, so it is probably best not to draw too many conclusions from it.  There are other parameters that also need to be taken into account which were not mentioned in the study, such as rate of exacerbations, albuterol usage, ER visits, hospitalizations to name a few.  Although Cinqair did reduce sputum eosinophils more than Nucala, a clinical correlation is still needed.

It is important to speak to your asthma doctor to see which biologic asthma medication is right for you if you have severe asthma.  There are many on the market and more are coming out in the near future.  The field of biologics for asthma is becoming very personalized and if you do have severe asthma that is not controlled by conventional asthma medication, it is important to find the right one which is best for you.

New Asthma Drug Nucala (Mepolizumab) for Severe Eosinophilic Asthma

Cinqair (Reslizumab) for Eosinophil Disorders (formerly Cinquil)

Fasenra (Benralizumab) for Severe Asthma

Tezepelumab for Severe Asthma

New Asthma Medications

 

 

Filed Under: Asthma, Blog

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

May 31, 2023

Understanding Yeast Allergy, am I Allergic to Yeast?

yeast allergy

May 23, 2023

Neffy, a New Epinephrine Nasal Spray

neffy

May 19, 2023

Broccoli Allergy: An Emerging Concern in Allergy

broccoli allergy

May 16, 2023

Xolair vs. Nucala vs. Dupixent in Asthma, which is the best?

Xolair vs. Nucala vs. Dupixent

May 10, 2023

Garlic Allergy, An Overview and its Benefits

garlic allergy

May 4, 2023

Oat Allergy: Symptoms, Diagnosis, and Treatment

oat allergy

May 3, 2023

Rice Allergy Overview, all you need to know

rice allergy

April 11, 2023

Banana Allergy Can Come in Many Flavors

banana allergy

April 9, 2023

Eggplant Allergy, an uncommon food allergen

eggplant allergy

April 7, 2023

Corn Allergy: Causes, Symptoms, and Treatment

corn allergy

Read More Posts...

Follow Us…

© 2023 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page